Last updated:
Author(s):
Manik Garg, Marcin Karpinski, Dorota Matelska, Lawrence Middleton, Oliver S. Burren, Fengyuan Hu, Eleanor Wheeler, Katherine R. Smith, Margarete A. Fabre, Jonathan Mitchell, Amanda O'Neill, Euan A. Ashley, Andrew R. Harper, Quanli Wang, Ryan S. Dhindsa, Slavé Petrovski, Dimitrios Vitsios
Publish date:
11 September 2024
Journal:
Nature Genetics
PubMed ID:
39261665

Abstract

The emergence of biobank-level datasets offers new opportunities to discover novel biomarkers and develop predictive algorithms for human disease. Here, we present an ensemble machine-learning framework (machine learning with phenotype associations, MILTON) utilizing a range of biomarkers to predict 3,213 diseases in the UK Biobank. Leveraging the UK Biobank’s longitudinal health record data, MILTON predicts incident disease cases undiagnosed at time of recruitment, largely outperforming available polygenic risk scores. We further demonstrate the utility of MILTON in augmenting genetic association analyses in a phenome-wide association study of 484,230 genome-sequenced samples, along with 46,327 samples with matched plasma proteomics data. This resulted in improved signals for 88 known (P < 1 × 10−8) gene-disease relationships alongside 182 gene-disease relationships that did not achieve genome-wide significance in the nonaugmented baseline cohorts. We validated these discoveries in the FinnGen biobank alongside two orthogonal machine-learning methods built for gene-disease prioritization. All extracted gene-disease associations and incident disease predictive biomarkers are publicly available (http://milton.public.cgr.astrazeneca.com).

Related projects

1. The primary scientific goal of the research is to apply human genetics to the identification of new drug targets, the validation of existing targets…

Institution:
Regeneron Genetics Center, LLC, United States of America

Whole genome sequencing of samples from the UK Biobank will lead to the identification of genetic variants within the human genome that can be associated…

Institution:
AstraZeneca AB, Sweden

All projects